Product Information
LIRAGLUTIDE 5-PAK 18 MG/3 ML is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $49.2481 per ML under NDC 00480725046. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Aug 27, 2025. Its Orange Book therapeutic-equivalence code is AP2.
Strength
6 mg/mL
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480725046
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
LIRAGLUTIDEApproval Type
Generic (ANDA)
FDA Application
ANDA214568FDA Approved
8/27/2025
TE Code
AP2
On Market Since
8/28/2025
Pharmacological Classes
Price Statistics
The NADAC for LIRAGLUTIDE 5-PAK 18 MG/3 ML has been published 42 times since Dec 17, 2025, and over the history we have for it it has declined 31.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.2481 per ML |
|---|---|
| All-time high | $73.7391 (Feb 11, 2026) |
| All-time low | $47.6947 (Aug 19, 2026) |
| 52-week high | $73.7391 |
| 52-week low | $47.6947 |
| Median price | $70.6417 |
| Average price | $65.1017 |
| Largest weekly change | -13.6% (Aug 19, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 38% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Liraglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LIRAGLUTIDE 5-PAK 18 MG/3 ML?
The current National Average Drug Acquisition Cost (NADAC) for LIRAGLUTIDE 5-PAK 18 MG/3 ML, manufactured by Teva Pharmaceuticals USA Inc., is $49.2481 per ML (NDC 00480725046), effective Sep 30, 2026.
How has the price of LIRAGLUTIDE 5-PAK 18 MG/3 ML changed over time?
Over the history we have for it, the NADAC for LIRAGLUTIDE 5-PAK 18 MG/3 ML has declined 31.4%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for LIRAGLUTIDE 5-PAK 18 MG/3 ML?
Since Dec 17, 2025, the NADAC for LIRAGLUTIDE 5-PAK 18 MG/3 ML has ranged from a low of $47.6947 (Aug 19, 2026) to a high of $73.7391 (Feb 11, 2026), with a median of $70.6417 per ML.
Are there cheaper alternatives to LIRAGLUTIDE 5-PAK 18 MG/3 ML?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIRAGLUTIDE 3-PAK 18 MG/3 ML, is $30.6324 per ML — about 38% below LIRAGLUTIDE 5-PAK 18 MG/3 ML.
Who manufactures LIRAGLUTIDE 5-PAK 18 MG/3 ML?
LIRAGLUTIDE 5-PAK 18 MG/3 ML (NDC 00480725046) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.